Roundtable Discussions
Opening Plenary: Enabling Access Through Innovation – Cell and Gene Therapy in 2023 and Beyond

Roundtable Discussions

19 Jan 2023

11:00am Introduction 

Join one of eight roundtable discussions, each focused on a critical area or bottleneck for cell and gene therapy developers going in to 2023. Each session is an open and interactive discussion guided by one moderator for the full hour.


Roundtable #1: TBC

Moderated by: Andy Holt, Chief Commercial Officer, Cellistic


Roundtable #2: Can Deeptech Improve Cell Therapy Precision, Turnaround Time and Yield in Cell and Gene Therapy? 

  • What are the new, upcoming innovation challenges- both in clinical practice and in discovery – with regards to manufacturing technology and analytical instrumentation and within what time frame are these needed?
  • How to optimize therapy development for solid vs. liquid tumors? How to work with challenges in patient profiling, precise transfection and multimarker cell selection. How to deal with manufacturing challenges coming from the above?
  • Where can deeptech (unique hardware, software and AI co-development) have an impact on cell and gene therapy manufacturing (modular, scalable, miniaturized, online)?
  • What collaboration forms are needed to enable this?

Moderated by: Peter Peumans, Chief Technical Officer Health, Imec


Roundtable #3

Moderated by: TBC


Roundtable #4: It Takes a Village: How Do We Build and Keep Great Teams?

  • Persevering through the current economic climate
  • Balancing money, time, expertise, and culture
  • Understanding, supporting, and empowering through alignment of corporate and individual motivations

Moderated by: Matt Li, Director, Cell Therapy CMC, Tome Biosciences


Roundtable #5  So You’ve Been Acquired: Successful Management and Integration From Both Sides of the Deal

  • Some large pharmas choose to have the acquired companies continue to operate mostly independently while others move forward with integration quickly. What do you think is the best strategy? What factors should contribute to that decision?
  • What are the biggest challenges you faced with integration? Biotech and Big pharma have very different cultures. How do you navigate the transition? What do you need to ensure effective change management? 
  • What are the key elements of a successful integration? (i.e. timing, strategy, change management etc)

Moderated by: Amy House, Chief Commercial Officer, Gyroscope Therapeutics x Novartis Gene Therapies


Roundtable #6: Delivering On Patient Advocacy for Breakthrough Therapeutics

Moderated by: Lisa Ward, Co-Founder, Tough2gether for DIPG/DMG


Roundtable #7

Moderated by: TBC


Roundtable #8

Moderated by: TBC


12:15pm Rapporteur Round-Up

With all session moderators


Amy House
Integration & Transition Lead, Former: Senior Director, Chief of Staff to Chief Medical Officer
Andy Holt
Chief Commercial Officer
Arnaud Deladeriere
Director of Process Development
Triumvira Immunologics
Lisa Ward
Tough2gether Against DIPG/DMG
Matthew Li
Director, Cell Therapy CMC
Tome Biosciences
Peter Peumans
Chief Technical Officer (Health)